Global Consensus Guides Safe Use of GLP-1 and Dual GLP-1/GIP Receptor Agonists in Type 1 Diabetes

Off-label use is becoming increasingly common to address weight management, insulin resistance, and complication risks in type 1 diabetes. New expert recommendations provide a framework for safe use while large trials are ongoing. SAN FRANCISCO, June 5, 2026 /PRNewswire/ -- A consensus...